Cyclosporine aplastic anemia with

Frickhofen N, Kaltwasser J, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991 324 1297-1304. 

Jiang TT, Huang W, Patel D. Cyclosporine-induced encephalopathy predisposed by diltiazem in a patient with aplastic anemia. Ann Pharmacother 1999 33(6) 750-1. 

The optimal immunosuppressive regimen is a combination of antithymocyte globuhn, glucocorticoids, and cyclosporine. Three-year survival rates can approach 90%, " which is comparable to that for HSCT, and makes immunosuppressive therapy a possible option for patients who are elderly (age >50 years), those who lack an eligible donor, and those who have less severe disease. A study comparing survival following immunosuppressive therapy or HSCT in patients with severe aplastic anemia found no significant difference between the treatment modalities at 6 years." These data provide... 

Bacigalupo A, Broccia G, Codra G, et al. Antilymphocyte globuUn, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA) A pilot study of the EBMT SAA Working Party. Blood 1995 85 1348-1353. 

Clinical use Lymphocyte immune globulin is used prior to bone marrow transplantation to prevent the graft-versus-host (GVH) reaction. It is also used in combination with cyclosporine or cytotoxic drugs (or both) for maintenance following bone marrow, heart, and renal transplantations. Lymphoc3 te immune globulin has induced remissions in patients with aplastic anemia. 

---